




SUPPLEMENTARY FIGURES




Supplementary Figure 1: CD133 overexpression in stable cell lines. (A) Gene expression in MIA, EV-MIA, and CD133^{hi}-MIA stable cell lines, (B) surface CD133 expression as determined by flow cytometry, and (C) CD133 gene expression upon CD133 siRNA silencing.




Supplementary Figure 2: CD133 overexpression increases cancer stem cell markers. (A) RNA expression of CXCR4 and ABCG2, (B) surface expression of CD133 and CXCR4 by flow cytometry, and (C) surface expression of ABCG2 by immunofluorescence.



Supplementary Figure 3: CD133 overexpression induces a more fibroblast-like morphology. (A) Representative images of MIA, EV-MIA, and CD133^{hi}-MIA cell lines.



Supplementary Figure 4: Silencing CD133 decreases invasion and NF-κB activity. (A) *In vitro* invasion represented as fold change normalized to S2-Vp10 control compared to LV-shRNA-αCD133 knockdown cell lines. (B) CD133 surface expression as determined by flow cytometry. (C) NF-κB activity in S2-Vp10 and shRNA derivatives by dual-luciferase assay. (D) Gene expression changes in EMT and "stemness" related genes upon silencing of CD133.



Supplementary Figure 5: Degree of CD133 surface overexpression correlates with “stemness” and invasion. (A) ALDH1 activity as measured by flow cytometry, (B) Dye efflux potential as determined by flow cytometry, and (C) *in vitro* invasion by Boyden chamber invasion assay.